Lantern Pharma (NASDAQ: LTRN) has entered into a partnership with Hoth Therapeutics (NASDAQ: HOTH) to apply its artificial intelligence platform PredictBBB.ai in streamlining drug development for central nervous system (CNS) conditions. The collaboration aims to leverage the platform's high accuracy in predicting whether drug candidates can cross the blood-brain barrier, a significant hurdle in treating neurological disorders.
PredictBBB.ai, which boasts a reported 94% accuracy rate, is designed to evaluate and predict the permeability of drug candidates across the blood-brain barrier. By integrating this technology, Hoth Therapeutics expects to reduce development risk, improve candidate selection, and accelerate timelines for bringing new therapies to patients. The platform is part of Lantern's broader RADR platform, which applies AI and machine learning to optimize oncology drug discovery and development, utilizing over 200 billion oncology-focused data points and a library of 200+ advanced algorithms.
Leaders from both companies emphasized the collaboration as a pivotal step toward accelerating the path to bring life-changing therapies to patients. The partnership underscores the growing role of AI in pharmaceutical research, particularly in addressing complex challenges such as CNS drug delivery. For more details, visit the full article at https://ibn.fm/NZoZD.
Lantern Pharma is an AI company focused on transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary RADR platform leverages vast data and advanced machine learning algorithms to address real-world problems in oncology. On average, Lantern's internally developed drug programs have advanced from initial AI insights to first-in-human clinical trials in two to three years at a cost of approximately $2.5 million per program. The company's pipeline spans multiple cancer indications, including solid tumors and blood cancers.
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for a variety of indications. The partnership with Lantern Pharma is expected to enhance Hoth's drug development capabilities for CNS disorders, potentially leading to more efficient and effective treatments. This collaboration highlights the increasing convergence of AI and biotechnology to solve longstanding challenges in drug discovery.
For more information about Lantern Pharma, visit the company's newsroom at https://ibn.fm/LTRN.
